Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Omeprazole: long-term safety.

R Arnold1, H Koop

  • 1Department of Internal Medicine, Philipps University, Marburg, FRG.

Digestion
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Omeprazole is a safe and well-tolerated medication for peptic diseases, with side effects comparable to H2 blockers. Studies show it does not significantly alter gastric endocrine cells in humans at recommended doses.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Choosing wisely recommendations in gastroenterology].

Der Internist·2017
Same author

[Erratum to: "Choosing wisely" in infectious diseases : Overuse of antibiotics - too few vaccinations].

Der Internist·2016
Same author

["Choosing wisely" in infectious diseases : Overuse of antibiotics - too few vaccinations].

Der Internist·2016
Same author

[S2k guideline: gastroesophageal reflux disease guided by the German Society of Gastroenterology: AWMF register no. 021-013].

Zeitschrift fur Gastroenterologie·2014
Same author

Concomitant use of thrombocyte aggregation inhibitors and proton pump inhibitors (PPIs).

Zeitschrift fur Gastroenterologie·2011
Same author

[Concomitant use of platelet aggregation inhibitors and proton pump inhibitors (PPIs): Position paper of the German Society for Digestive and Metabolic Diseases (DGVS) and the German Society of Cardiology (DGK).].

Zeitschrift fur Gastroenterologie·2010
Same journal

Directional Bias in Polyp Detection during Colonoscopy: A Prospective Observational Study.

Digestion·2026
Same journal

Prospective validation of magnified endoscopic examination with image-enhanced endoscopy as an optical biopsy for differentiating superficial duodenal epithelial tumor and non-neoplastic lesion in duodenum.

Digestion·2026
Same journal

Accurate imaging diagnosis of small pancreatic carcinoma/high-grade pancreatic intraepithelial neoplasia using combined indirect imaging findings.

Digestion·2026
Same journal

Restoration of gut microbiota dysbiosis by a probiotic Lactobacillus paragasseri OLL2716 in patients being treated with low-dose aspirin and acid-suppressive agents.

Digestion·2026
Same journal

Adverse Events after Colorectal Polypectomy in Patients with Amyloidosis: Risk Assessment Using Propensity Score Matching.

Digestion·2026
Same journal

Prognostic effect of MES 1 inflammatory extent on remission maintenance in ulcerative colitis.

Digestion·2026
See all related articles

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Toxicology

Background:

  • Omeprazole is a widely used proton pump inhibitor for treating acid-related gastrointestinal disorders.
  • Previous toxicological studies in animals indicated potential endocrine cell changes with high omeprazole dosages.

Purpose of the Study:

  • To evaluate the safety and tolerability of omeprazole in humans, particularly concerning its effects on gastric endocrine cells.
  • To compare the safety profile of omeprazole with H2-blocker treatments.

Main Methods:

  • Clinical experience from over 10,000 individuals.
  • Analysis of toxicological data from animal studies.
  • Assessment of gastric endocrine cell changes (G, D, and ECL cells) in patients treated with omeprazole for up to two years.

Related Experiment Videos

Main Results:

  • Omeprazole is safe and well-tolerated, with few side effects similar to H2 blockers.
  • High omeprazole doses in animals caused achlorhydria, hypergastrinemia, and ECL cell hyperplasia, a sequence linked to carcinoid tumors.
  • Therapeutic doses in humans do not cause complete achlorhydria, resulting in moderate gastrin level increases, and no significant changes in gastric endocrine cell densities were observed in patients over two years.

Conclusions:

  • Omeprazole is as safe as H2 blockers for treating peptic diseases when used at recommended dosages.
  • The gastrin-carcinoid sequence observed in rats is unlikely to occur in humans at therapeutic omeprazole doses.
  • Long-term omeprazole treatment (up to 2 years) did not result in significant alterations of gastric endocrine cell populations in patients.